Curated News
By: NewsRamp Editorial Staff
November 11, 2026
BioVersys and GSK to unveil new alpibectir TB data at Union Conference
TLDR
- BioVersys and GSK will present Phase 2 alpibectir data at the Union Conference, advancing a TB regimen with US and EU orphan exclusivity.
- Alpibectir potentiates ethionamide by inhibiting a transcriptional regulator, lowering the effective dose and overcoming resistance in M. tuberculosis.
- New alpibectir-ethionamide data could lead to safer, shorter tuberculosis treatments, improving outcomes for patients with drug-sensitive and resistant TB.
- BioVersys will share four alpibectir presentations at the Union World Conference on Lung Health in Rio de Janeiro from November 17 to 20, 2026.
Impact - Why it Matters
Tuberculosis remains one of the world’s deadliest infectious diseases, and the rise of drug-resistant strains poses a growing threat to global health. New treatment options are urgently needed. Alpibectir’s novel mechanism—potentiating ethionamide to lower doses and overcome resistance—could lead to shorter, safer, and more effective regimens for pulmonary TB and TB meningitis. The upcoming Phase 2 data presentation at the Union World Conference on Lung Health represents a critical step in the drug’s development, potentially bringing a much-needed therapy closer to patients. With orphan drug designations already granted in the US and EU, alpibectir holds promise to address significant unmet medical needs and improve outcomes for those affected by this devastating disease.
Summary
BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company based in Basel, Switzerland, has announced that it will present new data on its investigational tuberculosis drug alpibectir in collaboration with development partner GSK at the Union World Conference on Lung Health. The conference, which brings together researchers, practitioners, advocates, policymakers, and communities from around the world, will take place from 17 to 20 November 2026 in Rio de Janeiro, Brazil. The presentations will highlight the latest Phase 2 results on alpibectir in combination with ethionamide (AlpE) in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.
The data will be shared across multiple sessions, featuring presenters such as Dr. Simphiwe RN Simelane and Dr. Michel Pieren of BioVersys. Key presentations include an e-poster on the early bactericidal activity, safety, and pharmacokinetics of AlpE; a talk on alpibectir’s potentiation of ethionamide activity in clinical isolates of M. tuberculosis; and a session detailing results from the ENABLE trial. Additionally, Dr. Simon Tiberi will discuss updates on further development of alpibectir-containing TB regimens. Alpibectir, previously known as BVL-GSK098, is a small molecule derived from BioVersys’ award-winning Transcriptional Regulatory Inhibitory Compounds (TRIC) platform. It acts through a novel mode of action to potentiate ethionamide, aiming to lower the effective human dose, minimize side effects, and overcome resistance. The AlpE combination has received orphan-drug designation from the U.S. FDA in 2023 and Orphan Designation from the European Medicines Agency in 2025, providing incentives such as market exclusivity. BioVersys’ most advanced programs also include BV100 for Acinetobacter baumannii infections, currently in Phase 3.
For more information, visit the company’s website at www.bioversys.com or view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, BioVersys and GSK to unveil new alpibectir TB data at Union Conference
